Report Details:
15 Companies Covered
60 Pages
Market Research Future (MRFR) has published a comprehensive research report on the Global Diabetes Market, covering the forecast period from 2025 to 2035. According to the analysis, the Diabetes Market was valued at USD 6.86 billion in 2024 and is projected to grow significantly, reaching USD 13.77 billion by 2035, registering a compound annual growth rate (CAGR) of 6.54% during the forecast period.
MRFR identifies Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), Merck & Co. (US), Johnson & Johnson (US), Abbott Laboratories (US), Eli Lilly and Company (US), and AstraZeneca (GB) as the key players operating in the Global Diabetes Market.
Market Highlights
The Global Diabetes Market is accounted for to register a CAGR of 6.54% during the forecast period and is estimated to reach USD 13.77 billion by 2035.
The increasing prevalence of diabetes worldwide is a major factor driving market growth. Rising patient populations, expanding screening programs, and growing awareness regarding early diagnosis are accelerating the demand for advanced therapies, continuous glucose monitoring technologies, insulin delivery systems, and comprehensive long-term disease management solutions.
Technological advancements in diabetes care are significantly influencing market expansion. Innovations in continuous glucose monitoring (CGM) systems, smart insulin delivery devices, digital health platforms, mobile health applications, telemedicine, and AI-enabled patient monitoring are improving treatment outcomes while supporting personalized diabetes management.
Growing emphasis on preventive healthcare is further accelerating market demand. Public health campaigns promoting healthy lifestyles, early diagnosis, and risk awareness, combined with government initiatives focused on non-communicable disease prevention, are encouraging proactive diabetes management and reducing long-term healthcare burdens.
Additionally, the rapidly growing elderly population, increasing prevalence of obesity and lifestyle-related diseases, and expanding healthcare infrastructure are creating significant growth opportunities for diabetes treatment providers, medical device manufacturers, and digital healthcare companies worldwide.
Segment Analysis
The Global Diabetes Market is segmented based on Type of Diabetes, Treatment Method, Patient Demographics, Complications, Market Channel, and Region.
By Type of Diabetes, the market includes Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, LADA, and MODY. Type 2 Diabetes holds the largest market share due to its high global prevalence, accounting for nearly three-fourths of diabetes cases, along with increasing incidence driven by sedentary lifestyles and obesity. Type 1 Diabetes is the fastest-growing segment owing to improving diagnosis rates, increasing awareness, and advancements in insulin therapies and disease management technologies.
By Treatment Method, the market includes Insulin Therapy, Oral Medications, Dietary Management, Physical Activity, Continuous Glucose Monitoring, and Others. Insulin Therapy dominates the market due to its established clinical effectiveness and widespread use among patients with Type 1 diabetes and advanced Type 2 diabetes. Continuous Glucose Monitoring (CGM) is the fastest-growing segment as increasing adoption of digital health technologies and real-time glucose monitoring enhances disease management and patient outcomes.
Region Analysis
Regionally, the Global Diabetes Market is witnessing substantial growth across North America, Europe, Asia-Pacific, and the Rest of the World, supported by increasing diabetes prevalence, technological innovation, and expanding healthcare access.
North America holds the largest market share, accounting for nearly 69.97% of global revenue in 2024. Growth is supported by advanced healthcare infrastructure, high healthcare expenditure, widespread adoption of innovative diabetes therapies, favorable reimbursement policies, and strong awareness regarding diabetes management. The United States remains the major contributor due to its large diabetic population and continuous investments in digital healthcare technologies.
Europe represents the second-largest market, generating approximately USD 2.06 billion in revenue in 2024. The region benefits from growing healthcare expenditure, an aging population, supportive regulatory frameworks, and increasing adoption of advanced diabetes therapies across countries including Germany, France, the United Kingdom, and Italy.
Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rapid urbanization, increasing obesity rates, changing lifestyles, expanding healthcare infrastructure, and rising awareness regarding diabetes prevention and treatment. Countries including China, India, Japan, and South Korea are witnessing increasing investments in affordable diabetes management solutions and innovative healthcare technologies.
The Rest of the World, including South America and the Middle East & Africa, is also witnessing steady growth due to rising diabetes prevalence, improving healthcare infrastructure, expanding government initiatives for diabetes awareness, and increasing investments in chronic disease management across emerging economies.
Key Findings of the Study
- The Global Diabetes Market is projected to grow at a CAGR of 6.54% during the forecast period.
- The market is expected to reach USD 13.77 billion by 2035, driven by the increasing prevalence of diabetes, technological advancements, and growing healthcare expenditure.
- Type 2 Diabetes holds the largest market share due to its high prevalence, while Type 1 Diabetes is the fastest-growing type segment supported by advancements in diagnosis and treatment.
- Insulin Therapy remains the leading treatment segment, while Continuous Glucose Monitoring (CGM) is witnessing the fastest growth owing to rapid technological innovation and increasing adoption of digital health solutions.
- North America accounts for the largest regional market share, while Asia-Pacific is expected to register the fastest growth due to increasing diabetes prevalence, urbanization, and expanding healthcare access.
- Rising diabetes incidence, aging populations, increasing obesity rates, growing awareness regarding early diagnosis, and government healthcare initiatives remain the primary factors driving market growth.
- Increasing adoption of AI-enabled diabetes management platforms, digital therapeutics, telemedicine, continuous glucose monitoring technologies, and personalized treatment approaches is creating significant opportunities across the global diabetes care value chain.
- Novo Nordisk, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, and AstraZeneca are among the leading companies driving innovation and competition in the Global Diabetes Market.
